Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
about
Medication-related osteonecrosis of the jaw: Clinical and practical guidelinesEpidemiology and management of osteoporosis in the People's Republic of China: current perspectivesTeriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment.A reappraisal of generic bisphosphonates in osteoporosis.Emerging applications of anticytokine vaccines.Prevention of osteoporosis-related fractures among postmenopausal women and older men.Can lumbar spine bone mineral density predict readmission in denosumab-treated patients with chronic kidney disease?Choosing a treatment for patients at the time a fracture is presented.Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density.Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review.Recommendations on the management of fragility fracture risk in women younger than 70 years.Osteoprotegerin autoantibodies do not predict low bone mineral density in middle-aged women.Dental students' knowledge of medication-related osteonecrosis of the jaw.Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer.Sortase A-aided Escherichia coli expression system for functional osteoprotegerin cysteine-rich domain.Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy.Secretomes from mesenchymal stem cells participate in the regulation of osteoclastogenesis in vitro.Denosumab - a new medication in the treatment of postmenopausal osteoporosis.Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study.The Biological Enhancement of Spinal Fusion for Spinal Degenerative DiseaseEffects of denosumab on fracture and bone mineral density by level of kidney function
P2860
Q26749965-C5F0A92C-84BC-476D-AF0A-8D47303CA223Q27005978-C4F60C4E-0CA5-47D4-8854-638214C28EB5Q30627873-CE60B13A-D6B2-4E4F-A453-124356D61BC4Q30755058-A54B338A-DA52-4710-A510-2A45023E97D3Q35613817-2FFF4A2A-6255-467D-B005-B1E36EF5B02BQ35644168-55B1952B-8969-4CEB-972F-BAAC12168F26Q37340457-0014070C-C1A4-48F0-82F2-172DF4B02B6FQ37428448-00C2827A-BB6E-42C8-8F7F-63E65686ECE1Q37616992-BEB8760C-767F-4EC3-9C90-534D3C329524Q37886780-92BC4332-5F39-4417-8AF9-184DB131CA17Q38339579-ED4D8D32-D971-413A-A53D-49C05A055293Q38984955-8D7542AD-CC20-4CA1-8592-A422EB32E8F3Q39130990-BC8A07E2-6CD3-4AEC-8F3C-FEE421E5F93BQ44278781-2F22E5BA-6A28-47EB-86A0-5D9576860C31Q47108020-A1566288-5166-4A5A-BBA7-F6A5A5A4E58BQ47149046-B869391E-BC6C-48C9-B480-5BE55937C55DQ50108898-93F49FEC-10D5-4B60-B871-CC79B4622641Q50673485-C4EFF1F9-23EE-4D3F-B847-7D1AAA16A7C5Q50947041-9FD61CB0-40E4-4043-9C86-A7FAE2000E79Q51740878-1558F78D-471A-4AB3-8055-BE3B2A90555AQ52673042-C22F828D-D433-43DC-88BB-80C82E9E0283Q55498037-3EC97169-E861-44DB-B5BC-DA59A3692149Q57168746-78450F36-F0C7-4E2B-99B2-E1FFAFC402ECQ58970644-BA340EB3-4826-4348-92D1-799DC9D538C3
P2860
Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical potential of RANKL in ...... other metabolic bone diseases.
@en
Clinical potential of RANKL in ...... other metabolic bone diseases.
@nl
type
label
Clinical potential of RANKL in ...... other metabolic bone diseases.
@en
Clinical potential of RANKL in ...... other metabolic bone diseases.
@nl
prefLabel
Clinical potential of RANKL in ...... other metabolic bone diseases.
@en
Clinical potential of RANKL in ...... other metabolic bone diseases.
@nl
P1476
Clinical potential of RANKL in ...... other metabolic bone diseases.
@en
P2093
Pierre D Delmas
P304
P356
10.1016/J.JOCD.2008.02.002
P577
2008-04-02T00:00:00Z